Prelude Capital Management, LLC Travere Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$5.26 - $8.28 $130,448 - $205,343
24,800 Added 30.09%
107,222 $881,000
Q1 2024

May 15, 2024
BUY
$7.18 - $9.82 $387,720 - $530,280
54,000 Added 189.99%
82,422 $635,000
Q4 2023

Feb 14, 2024
BUY
$5.44 - $9.5 $154,615 - $270,009
28,422 New
28,422 $255,000
Q1 2021

May 17, 2021
SELL
$23.37 - $31.77 $1.86 Million - $2.53 Million
-79,528 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$19.17 - $27.87 $1.52 Million - $2.22 Million
79,528 New
79,528 $2.17 Million

Others Institutions Holding TVTX

# of Institutions
192
Shares Held
84.5M
Call Options Held
776K
Put Options Held
900K
View Full List

About Travere Therapeutics, Inc.

TVTX Quotes by TradingView
  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.12B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email